Company and Stock Identity

How Owkin Connects to the Public Market

Company structure
Private company
Market access
No current public listing was verified.
Research focus
Separate research-platform agreements from drug-development milestones. Repeatable analysis and experimental validation answer different questions.

Owkin is privately held. Company sources are the starting point for ownership and business updates.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... Owkin ... Company source

Owkin and Estonia will test AI research inside national health-data systems

Owkin and Estonia's applied research center Metrosert announced an evaluation of K Pro within secure national infrastructure. The first phase will use selected health-data groups and explore research areas including oncology.

Why it matters: The collaboration tests whether AI research can work within national data controls. It is an evaluation plan, so useful evidence will come from repeatable analyses and the research produced.

... Owkin ... Company source

Sanofi signs a five-year licence for Owkin's K Pro and asks for AI agents built for its own teams

Owkin announced on 5 June 2026 a five-year licence with Sanofi for K Pro, the product Owkin calls its AI Scientist, together with work to build what it describes as next-generation biopharma agents purpose-built for Sanofi. Owkin says the agents are meant to act as assistants that carry out complex tasks in drug research and development on their own, across the span from early discovery through clinical development, and to support competitive intelligence and decision-making. The announcement discloses no financial terms. Thomas Clozel, Owkin's co-founder and chief executive, is quoted saying that building on the existing collaboration with Sanofi marks a shift toward truly embedded AI. Emmanuel Frenehard, Sanofi's chief digital officer, is quoted saying that putting purpose-built agentic systems into the company's workflows is meant to let its teams work with greater speed, depth and confidence.

Why it matters: The length is the signal. A five-year licence has to survive budget reviews and a change of leadership, which a one-year pilot does not, so Sanofi has committed to living with this software rather than testing it. Two things are worth holding at arm's length. No money was disclosed, so the term tells you about intent and not about scale. And the word autonomous is doing a lot of work: an agent that writes a research summary without being asked is useful, while an agent that prioritises which molecule to pursue is a decision, and the announcement does not separate the two. Note also that Sanofi's chief digital officer is the named executive rather than a research leader, which suggests this started as a digital programme.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: Biomedical research teams work with AI and software engineers. Clinical partnerships connect the work with hospitals and drug developers.

Qualification signal: Biomedical roles need training that fits the research. Technical work benefits from evidence that analyses can be reproduced on complex health data.

Check current roles at Owkin. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Pharmaceutical R&D, biotechnology leadership, translational science, business development, and investors
Primary use case
Identify targets, design molecules, prioritize experiments, and connect biomedical data to research decisions
Typical deployment
Ranges from software and data partnerships to platform collaborations and internally owned drug pipelines

Evidence questions

  • Which results are prospective, reproduced, and tied to a clinical or experimental endpoint?
  • How many programs are AI-originated, AI-assisted, partnered, or internally owned?
  • What has advanced beyond target identification and preclinical reporting?

Regulatory and workflow questions

  • Which entity owns development, validation, and regulatory responsibility for each program?
  • How are model-generated hypotheses reviewed before experimental or clinical use?
  • What claims are about research productivity versus a regulated product?

Data and contract questions

  • Who owns generated molecules, targets, models, and derived data?
  • Which proprietary datasets create defensibility and which are licensed?
  • Can a partner reproduce outputs and export project data after the collaboration?

Evidence and Regulation

FDA Clearances on Record

No clearance is linked in this directory. That is not automatically a mark against the company. Some products support the people doing the work instead of reading a patient image or signal themselves.

First-Hand Sources